Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
We showed a meaningful relationship of CDKN2A/B with the risk of breast cancer, cancer, showing the importance of studies in great sample size and several centers for studying the value of the marker as a risk classification in the management of patients with breast cancer.
|
31721206 |
2020 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Deregulation of the cyclin D-CDK4/6-INK4-RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer.
|
30478914 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The frequency of p16 hypermethylated breast cancer cases was significantly higher in TNBC than in ER+PR+Her2- group (33; 54.1% vs. 20; 28.6%, p=0.00298).
|
30003738 |
2019 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, qRT-PCR analysis revealed that Gemini-Cur could effectively upregulate the expression of p16INK4a, p14ARF and Bax, while significantly decreasing the Bcl-2 expression in these breast cancer cells.
|
30776589 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Two core genes, SRC proto‑oncogene non‑receptor tyrosine kinase and cyclin‑dependent kinase inhibitor 2A, were identified as serving a vital role in the onset and development of breast cancer, and their expression levels were markedly reduced following cinobufotalin treatment as detected by the microarray of GSE85871.
|
30896874 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expressions of both FHIT and p16 genes and proteins in breast cancer tissues were remarkably lower than those in cancer-adjacent and normal tissues (p<0.05 in all comparisons).
|
30941950 |
2019 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Six SNPs were associated with all-cause (CDKAL1-rs981042, P = 0.0032; HHEX-rs1111875, P = 0.0361; and INSR-rs919275, P = 0.0488) or BC-specific (CDKN2A/CDKN2B-rs3218020, P = 0.0225; CDKAL1-rs981042, P = 0.0246; and TCF2/HNF1B-rs3094508, P = 0.0344) mortality in additive genotype models, at α = 0.05.
|
30457165 |
2019 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The long non-coding RNA (LncRNA) antisense RNA in the INK4 locus (<i>ANRIL</i>) is overexpressed in several cancers including breast cancer.
|
31572679 |
2019 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Earlier studies have shown that CDKN2A excludes the predisposition of germline variants, but interestingly shares common breast cancer germline variants with other carcinomas.
|
30039340 |
2019 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our investigations demonstrated that the MTHFR rs180113 and CDKN2A/B rs10811661 had a significant correlation with the elevated risk of breast cancer and they might be potentially valuable to apply as a prognostic factor for individual health care.
|
30362613 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Identification of miR-146a is Associated with the Aggressiveness and Suppresses Proliferation via Targeting CDKN2A in Breast Cancer.
|
29915929 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that 9p21.3 (CDKN2A) loss and PIK3CA mutation characterize a subgroup of metaplastic breast cancers with myoepithelial and spindle cell differentiation.
|
29708279 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Five further patients (5 of 83; 6% of cohort) were found to harbor pathogenic variants in genes lacking a firm association with breast cancer susceptibility to date (i.e., Fanconi pathway genes, RECQ family genes, CDKN2A/p14<sup>ARF</sup>, and RUNX1).
|
30086788 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
There was a significant correlation between the presence of MMTV (identified by p14 immunohistochemistry) in human breast cancers and histological characteristics similar to MMTV positive mouse mammary tumors (<i>p</i> = 0.001).
|
29868468 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of breast cancer cell growth by the combination of clofarabine and sulforaphane involves epigenetically mediated CDKN2A upregulation.
|
29634384 |
2018 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, CIC formation negatively correlates with p16INK4a expression in human breast cancers.
|
29904067 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, DAPK, hMLH1, and p14 genes promoter hypermethylation were significantly associated with the susceptibility of breast cancer.
|
30572486 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We demonstrated that patients carrying the TT genotype for CDKN2A/B rs10811661 polymorphism had the increased risk of breast cancer susceptibility.
|
28276595 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, the effect of P16 inhibition on the tumor growth was verified with a BC xenograft mice model.
|
29388151 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
After eliciting a prior history of multiple primary melanomas and breast cancer, she was tested for and shown to be a carrier for a germline mutation in CDKN2A.
|
29110637 |
2017 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.
|
28551632 |
2017 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Epoxy clerodane diterpene inhibits MCF-7 human breast cancer cell growth by regulating the expression of the functional apoptotic genes Cdkn2A, Rb1, mdm2 and p53.
|
28068628 |
2017 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Western blot and immunochemistry were employed to evaluate the level of CtBP2 and p16INK4A in breast cancer.
|
28412731 |
2017 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our analysis of the RB-positive MCF-7 and ZR75.1 breast cancer cell lines revealed a lack of endogenous p16 protein expression as a result of the homozygous deletion and methylation of the p16 gene at the CDKN2A locus, respectively.
|
28243323 |
2017 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this report we identified differential regulation of the annexin/S100A family, through unique peptide recognition at the N-terminal regions, demonstrating p14ARF-p53 is a central orchestrator of the annexin/S100A family of calcium regulators in favor of pro-survival functions in the breast cancer cell.
|
28068434 |
2017 |